AngioDynamics gab bekannt, dass seine Machbarkeitsstudie zu Relief, in der die Nanoknife-Plattform für irreversible Elektroporation (IRE) als minimalinvasive Behandlung der benignen Prostatahyperplasie (BPH) untersucht wird, von der US-amerikanischen Arzneimittelbehörde FDA die Genehmigung im Rahmen einer Ausnahmeregelung für Prüfpräparate (Investigational Device Exemption, IDE) erhalten hat. – Bitget
AngioDynamics公司宣布，其用于评估Nanoknife不可逆电穿孔（IRE）平台作为良性Benign prostatic hyperplasia（BPH）微创治疗方案的Relief可行性研究，已获得美国食品药品监督管理局（FDA…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
よくある質問
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
